Jennison Associates LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 0.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 410,041 shares of the insurance provider’s stock after selling 1,601 shares during the period. Jennison Associates LLC owned 0.28% of Humana worth $98,664,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of HUM. Quantitative Systematic Strategies LLC acquired a new position in shares of Humana during the first quarter valued at about $375,000. Columbus Circle Investors raised its position in shares of Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock valued at $2,808,000 after buying an additional 6,722 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Humana during the first quarter valued at about $342,000. Hermes Investment Management Ltd. raised its position in shares of Humana by 0.9% in the first quarter. Hermes Investment Management Ltd. now owns 78,911 shares of the insurance provider’s stock valued at $16,267,000 after buying an additional 700 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its position in shares of Humana by 4.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 3,976 shares of the insurance provider’s stock valued at $766,000 after buying an additional 158 shares during the last quarter. Institutional investors own 99.13% of the company’s stock.

Humana Inc. (NYSE:HUM) opened at 247.28 on Monday. Humana Inc. has a one year low of $163.50 and a one year high of $255.27. The firm has a market capitalization of $35.74 billion, a P/E ratio of 20.34 and a beta of 0.91. The firm’s 50-day moving average price is $241.05 and its 200 day moving average price is $224.57.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The firm had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same period last year, the firm earned $2.30 earnings per share. On average, equities analysts anticipate that Humana Inc. will post $11.55 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. Humana’s dividend payout ratio (DPR) is currently 13.06%.

COPYRIGHT VIOLATION NOTICE: “Humana Inc. (HUM) Position Decreased by Jennison Associates LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/21/humana-inc-hum-position-decreased-by-jennison-associates-llc.html.

Several equities analysts have recently issued reports on HUM shares. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research note on Monday, April 24th. Cowen and Company reiterated an “outperform” rating and issued a $230.00 price target on shares of Humana in a research note on Tuesday, April 25th. Evercore ISI reiterated an “outperform” rating and issued a $240.00 price target on shares of Humana in a research note on Tuesday, April 25th. Cantor Fitzgerald lifted their price target on Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Wednesday, April 26th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $230.00 price target (up previously from $221.00) on shares of Humana in a research note on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. Humana presently has a consensus rating of “Hold” and an average price target of $244.35.

In other news, VP M Todoroff Christopher sold 22,935 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the transaction, the vice president now directly owns 24,001 shares of the company’s stock, valued at $6,060,732.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $251.88, for a total value of $3,022,560.00. Following the transaction, the chief executive officer now directly owns 80,086 shares in the company, valued at $20,172,061.68. The disclosure for this sale can be found here. Insiders have sold 41,406 shares of company stock worth $10,355,086 over the last ninety days. Insiders own 0.80% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.